Silence Therapeutics PLC Sponsored ADR (SLN) vs Valneva SE Sponsored ADR (VALN)

Silence Therapeutics PLC Sponsored ADR and Valneva SE Sponsored ADR are both Biotechnology companies. Silence Therapeutics PLC Sponsored ADR and Valneva SE Sponsored ADR are of similar size ($581.1M and $560.4M). Silence Therapeutics PLC Sponsored ADR has negative trailing earnings, so its P/E is not meaningful; Valneva SE Sponsored ADR trades at 59.7×. Valneva SE Sponsored ADR grew revenue faster over the last twelve months: −53.2% against −97.0%. Silence Therapeutics PLC Sponsored ADR has the higher net margin (0.00% vs −12.0%) and the higher return on invested capital (0.00% vs 0.00%). Across the 16 metrics below, Valneva SE Sponsored ADR leads on 10 and Silence Therapeutics PLC Sponsored ADR on 6.

Valuation

Metric SLN VALN Biotechnology median
P/E n/m 59.68 8.50
P/S 488.70 3.05 9.71
P/B 10.66 5.30 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m 42.91 0.64
EV/Sales 402.90 3.49 9.21
Earnings yield (14.75%) 1.68% (33.15%)
Free cash flow yield (10.32%) (11.78%) (25.50%)

Profitability

Metric SLN VALN Biotechnology median
Gross margin 79.50% 38.28% 65.16%
Operating margin 0.00% 13.56% 0.00%
Net margin 0.00% (12.01%) 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (90.41%) 0.00% (56.36%)
Return on assets (44.14%) 0.00% (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric SLN VALN Biotechnology median
Revenue growth (TTM) (96.97%) (53.16%) 6.02%
EPS growth (last fiscal year) (90.91%) (805.88%) 30.26%
Revenue growth, 5-year CAGR (39.74%) 9.41% 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric SLN VALN Biotechnology median
Debt to equity 0.00 2.27 0.00
Current ratio 7.42 2.16 4.72
Net debt to EBITDA 0.94 (1.15) 0.96

Dividend

Metric SLN VALN Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric SLN VALN Biotechnology median
Market cap 581.10m 560.39m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack